Carlos Pelayo Hernández Fernández

Carlos Pelayo Hernández Fernández

Auto-generated profile, based on publicly available information

Carlos Pelayo Hernández Fernández

Servicio de Dermatología. Hospital Universitario de Gran Canaria Doctor Negrín. Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, España

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2021 in Acta Dermato-Venereologica
Verified
Journal Article
Open access
CHC Hernández-Fernández
C Hernández-Fernández
GCG Carretero
G Carretero
RRR Rivera
R Rivera
CFCarlos Ferrándiz
Carlos Ferrándiz
EDEsteban Dauden
Esteban Dauden
AGa Group
a Group
The effect of gender on systemic therapy for psoriasis has not been well studied. The aim of this st...

9 January 2017 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
CZCamila Cabello Zurita
Camila Cabello Zurita
MPMercè Grau Pérez
Mercè Grau Pérez
CFCarlos Pelayo Hernández Fernández
Carlos Pelayo Hernández Fernández
AQAlicia González Quesada
Alicia González Quesada
PAPedro Valerón Almazán
Pedro Valerón Almazán
GCGregorio Carretero
Gregorio Carretero
Background: Methotrexate (MTX), a traditional antipsoriatic drug, is very frequently used either as monotherapy or in combination with other systemic drugs. Objectives: To assess the effectiveness and safety of MTX in psoriasis in usual clinical practice. Methods: We conducted a retrospective study. We performed an electronic and manual chart review of patients treated with MTX in the Psoriasis Unit of our Hospital from January 2007 to December 2014. Demographic and clinical data, PASI/DLQI scores and reasons for suspension of all patients treated with MTX in usual clinical practice were recorded. Results: Two hundred and eighteen patients were included. MTX was administered in 67% of cases as the first systemic treatment. The average treatment duration was 17.2 ± 13.6 months. All patients were subjected to clinical and laboratory monitoring. About 33.5% of them achieved a reduction of 75% or more of the initial PASI at week 12, 34.9% at week16, 44.7% at week 24, and 52.8% at week 48. A 3.3% had to discontinue the therapy due to analytical hepatic (2.8%) or renal (0.5%) abnormalities. Only one patient experienced severe interstitial pneumonitis and none required liver biopsy. Conclusions: MTX is an effective and safe option for the treatment of psoriasis in the real-world clinical practice.

1 December 2022 in Contact Dermatitis
Verified
Journal Article
Closed access
CFCarlos Pelayo Hernández Fernández
Carlos Pelayo Hernández Fernández
LBLeopoldo Borrego
Leopoldo Borrego
PGPedro Mercader García
Pedro Mercader García
AGAna M. M Giménez-Arnau
Ana M. M Giménez-Arnau
JPJavier Sánchez Pérez
Javier Sánchez Pérez
IDIgnacio García Doval
Ignacio García Doval

1 October 2021 in Actas Dermo-Sifiliograficas
Verified
Journal Article
Open access
CHC.P. Hernández-Fernández
C.P. Hernández-Fernández
PMP. Mercader-García
P. Mercader-García
JSJ.F. Silvestre Salvador
J.F. Silvestre Salvador
JPJ. Sánchez Pérez
J. Sánchez Pérez
VRV. Fernández Redondo
V. Fernández Redondo
LBLeopoldo Borrego
Leopoldo Borrego

13 February 2024 in Contact Dermatitis
Verified
Journal Article
Open access
CFCarlos Pelayo Hernández Fernández
Carlos Pelayo Hernández Fernández
LBLeopoldo Borrego
Leopoldo Borrego
AGAna M. M Giménez-Arnau
Ana M. M Giménez-Arnau
VNVioleta Zaragoza Ninet
Violeta Zaragoza Ninet
TSTatiana Sanz Sánchez
Tatiana Sanz Sánchez
IDIgnacio García Doval
Ignacio García Doval
Background: Current frequency and features for positivity to textile dye mix (TDM) in Spain are unknown.Objectives: To study the frequency, clinical features and simultaneous positivity between TDM, para‐phenylenediamine (PPD) and specific disperse dyes.Materials and Methods: We analysed all consecutive patients patch‐tested with TDM from the Spanish Contact Dermatitis Registry (REIDAC), from 1 January 2019 to 31 December 2022. Within this group, we studied all selected patients patch‐tested with a textile dye series.Results: Out of 6128 patients analysed, 3.3% were positive to the TDM and in 34% of them, the sensitization was considered currently relevant. TDM positivity was associated with working as a hairdresser/beautician and scalp, neck/trunk and arm/forearm dermatitis. From TDM‐positive patients, 57% were positive to PPD. One hundred and sixty‐four patients were patch‐tested with the textile dye series. Disperse Orange 3 was the most frequent positive dye (16%). One of every six cases positive to any dye from the textile dye series would have been missed if patch‐tested with the TDM alone.Conclusions: Positivity to TDM is common in Spain and often associated with PPD sensitization. TDM is a valuable marker of disperse dyes allergy that should be part of the Spanish and European standard series.

9 October 2025 in Actas Dermo-Sifiliograficas
Verified
Journal Article
Open access
CFC.P. Hernández Fernández
C.P. Hernández Fernández
LBL. Borrego
L. Borrego
AAA.M. Giménez Arnau
A.M. Giménez Arnau
TST. Sanz Sánchez
T. Sanz Sánchez
JCJ.M. Carrascosa Carrillo
J.M. Carrascosa Carrillo
MDM.A. Gallego Descalzo
M.A. Gallego Descalzo
Hydroxyisohexyl 3-cyclohexene carboxaldehyde (HICC), or Lyral® is a fragrance marker that is part of the Fragrance Mix II (FM II) and is still patched as an independent allergen within the European and other baseline series despite the European Commission banning its use in cosmetics in 2021. We aimed to study the prevalence of sensitization to the HICC in Spain and its simultaneous positivity with the FM II to determine whether it should be part of the Spanish standard path test series. We analysed all consecutive patients simultaneously patch-tested with HICC and FM II from the Spanish Contact Dermatitis Registry (REIDAC) from June 1st, 2018 through December 31st, 2023. A total of 96 (0.8%) out of 12,029 patients analyzed tested positive to HICC and 396 (3.3%) to FM II. In 53% and 64% of the patients, respectively, findings were considered currently relevant. A total of 72 out of 96 (75%) HICC positives would be detected if only FM II were patched. Prevalence of HICC sensitization in Spain is low and has decreased in recent years. HICC is a prohibited fragrance in cosmetics and FM II detects 3 in 4 sensitized patients. Our results suggest that HICC should remain outside the Spanish standard patch test series and support its exclusion from the European standard patch test series.